InvestorsHub Logo
Followers 132
Posts 8935
Boards Moderated 2
Alias Born 06/01/2013

Re: None

Friday, 01/03/2025 3:55:34 PM

Friday, January 03, 2025 3:55:34 PM

Post# of 33346
$ENDV Benefits for Common Shareholders from the SofPulse Transaction
Stock Dividend or Alternative Mechanism:

As part of the agreement, 80% of the $50 million in restricted stock (priced at $5.00 per share) from SofPulse, Inc. will be issued to Endonovo’s (ENDV) shareholders. This provides a direct benefit to common shareholders, effectively transferring a portion of the value from the sale to them.
Potential Uplisting to NASDAQ:

SofPulse, Inc. has committed to fulfilling regulatory requirements for a NASDAQ listing. This uplisting could significantly increase the liquidity and perceived value of the issued shares, benefiting shareholders holding the restricted stock.
Additional Valuation-Based Payments:

A third-party valuation may determine the assets' value to be higher than $50 million (up to $100 million). The difference will be issued to ENDV in the form of a senior note, which could further increase the benefits distributed to shareholders.
Strengthened Future Prospects:

SofPulse’s plans for substantial growth, including:
Expanding Federal Supply Schedule contracts with the VA and Department of Defense.
Developing international markets.
Targeting annual revenues of $100 million by 2025.
Shareholders may benefit if the company achieves these projections and their issued shares gain value over time.
ENDV's Continued Operations:

ENDV will retain its telehealth division and mergers/acquisitions division, providing shareholders with additional growth opportunities in other sectors.
Capital Raise and Strategic Expansion:

SofPulse’s $500,000 capital raise at a pre-money valuation of $10 million may position the company for sustained growth, indirectly supporting shareholder value.